• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea.

作者信息

Kim Ji Hye, Park Hae Sim, Ye Young Min, Shin Yoo Seob, Kang Hye Ryun, Chung Soo Jie, Choi Jeong Hee

机构信息

Division of Pulmonology and Allergy, Konyang University Hospital, Daejeon, Korea.

Department of Allergy and Clinical Immunology, Ajou University Hospital, Suwon, Korea.

出版信息

Allergy Asthma Immunol Res. 2020 Sep;12(5):894-896. doi: 10.4168/aair.2020.12.5.894.

DOI:10.4168/aair.2020.12.5.894
PMID:32638568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7346988/
Abstract
摘要

相似文献

1
Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea.奥马珠单抗治疗胆碱能性荨麻疹患者：韩国的一项真实世界回顾性研究。
Allergy Asthma Immunol Res. 2020 Sep;12(5):894-896. doi: 10.4168/aair.2020.12.5.894.
2
Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.奥马珠单抗治疗青少年和成人慢性特发性（自发性）荨麻疹患者的获益和危害：“真实世界”证据的荟萃分析。
JAMA Dermatol. 2019 Jan 1;155(1):29-38. doi: 10.1001/jamadermatol.2018.3447.
3
Real-life treatment of cholinergic urticaria with omalizumab.奥马珠单抗治疗胆碱能性荨麻疹的实际应用
J Allergy Clin Immunol. 2019 Feb;143(2):788-791.e8. doi: 10.1016/j.jaci.2018.08.050. Epub 2018 Oct 9.
4
Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria.慢性特发性荨麻疹患者使用奥马珠单抗的真实世界治疗模式及疗效
Curr Med Res Opin. 2018 Jan;34(1):35-39. doi: 10.1080/03007995.2017.1395732. Epub 2017 Nov 10.
5
[Omalizumab for the treatment of chronic urticaria: Real-life findings].奥马珠单抗治疗慢性荨麻疹：真实世界研究结果
Ann Dermatol Venereol. 2019 Jan;146(1):9-18. doi: 10.1016/j.annder.2018.07.031. Epub 2019 Jan 9.
6
Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.奥马珠单抗单药或联合治疗慢性自发性荨麻疹的有效性和安全性的真实世界数据：一项回顾性队列研究。
J Dermatolog Treat. 2020 Mar;31(2):204-209. doi: 10.1080/09546634.2019.1589639. Epub 2019 Mar 7.
7
Omalizumab in Chronic Urticaria: An Italian Survey.奥马珠单抗治疗慢性荨麻疹：一项意大利的调查。
Int Arch Allergy Immunol. 2019;178(1):45-49. doi: 10.1159/000492532. Epub 2018 Nov 5.
8
The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.奥马珠单抗对慢性自发性荨麻疹患者生活质量的影响及其预测因素：真实世界数据。
Dermatol Ther. 2019 Jul;32(4):e12975. doi: 10.1111/dth.12975. Epub 2019 Jun 25.
9
The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey.奥马珠单抗治疗难治性慢性自发性荨麻疹的疗效与安全性：土耳其的真实病例经验
Acta Dermatovenerol Alp Pannonica Adriat. 2018 Sep;27(3):121-126.
10
The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.在西澳大利亚门诊队列中，奥马珠单抗治疗难治性慢性自发性荨麻疹的应用。
Intern Med J. 2019 Apr;49(4):526-528. doi: 10.1111/imj.14245.

引用本文的文献

1
Altered Sweat Composition Due to Changes in Tight Junction Expression of Sweat Glands in Cholinergic Urticaria Patients.胆碱能性荨麻疹患者因汗腺紧密连接表达改变而导致汗液成分改变。
Int J Mol Sci. 2024 Apr 25;25(9):4658. doi: 10.3390/ijms25094658.
2
Cholinergic Urticaria: Subtype Classification and Clinical Approach.胆碱能性荨麻疹：亚型分类与临床处理方法。
Am J Clin Dermatol. 2023 Jan;24(1):41-54. doi: 10.1007/s40257-022-00728-6. Epub 2022 Sep 15.
3
Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.

本文引用的文献

1
Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.奥马珠单抗（茁乐）治疗抗组胺药加倍治疗仍无效的胆碱能性荨麻疹的疗效和安全性：一项随机、混合、双盲、开放标签、安慰剂对照的临床试验。
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1599-1609.e1. doi: 10.1016/j.jaip.2018.12.025. Epub 2019 Jan 15.
2
Real-life treatment of cholinergic urticaria with omalizumab.奥马珠单抗治疗胆碱能性荨麻疹的实际应用
J Allergy Clin Immunol. 2019 Feb;143(2):788-791.e8. doi: 10.1016/j.jaci.2018.08.050. Epub 2018 Oct 9.
3
奥马珠单抗治疗慢性自发性荨麻疹和慢性诱导性荨麻疹：疗效的真实世界研究及治疗结局的预测因素。
J Korean Med Sci. 2022 Jul 11;37(27):e211. doi: 10.3346/jkms.2022.37.e211.
Chronic inducible urticaria: A systematic review of treatment options.
慢性诱导性荨麻疹：治疗选择的系统评价。
J Allergy Clin Immunol. 2018 May;141(5):1726-1734. doi: 10.1016/j.jaci.2018.01.031. Epub 2018 Feb 10.
4
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.欧洲过敏研究学会/过敏标准委员会/欧洲皮肤病学会/世界变态反应组织荨麻疹指南：定义、分类、诊断和管理。
Allergy. 2018 Jul;73(7):1393-1414. doi: 10.1111/all.13397.
5
Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence.奥马珠单抗治疗慢性诱导性荨麻疹患者：已发表证据的系统评价。
J Allergy Clin Immunol. 2018 Feb;141(2):638-649. doi: 10.1016/j.jaci.2017.06.032. Epub 2017 Jul 24.
6
Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management.胆碱能性荨麻疹：流行病学、病理生理学、新分类和管理。
Clin Auton Res. 2018 Feb;28(1):103-113. doi: 10.1007/s10286-017-0418-6. Epub 2017 Apr 5.